Accumulating evidences demonstrated that the induction of epithelial-mesenchymal transition (EMT) and aberrant expression of microRNAs (miRNAs) are associated with tumorigenesis, tumor progression, metastasis and relapse in cancers, including chronic myeloid leukemia (CML). We found that miR-320a expression was reduced in K562 and in CML cancer stem cells. Moreover, we found that miR-320a inhibited K562 cell migration, invasion, proliferation and promoted apoptosis by targeting BCR/ABL oncogene. As an upstream regulator of BCR/ABL, miR-320a directly targets BCR/ABL. The enhanced expression of miR-320a inhibited the phosphorylation of PI3K, AKT and NF-κB; however, the expression of phosphorylated PI3K, AKT and NF-κB were restored by the overexpression of BCR/ABL. In K562, infected with miR-320a or transfected with SiBCR/ABL, the protein levels of fibronectin, vimentin, and N-cadherin were decreased, but the expression of E-cadherin was increased. The expression of mesenchymal markers in miR-320a-expressing cells was restored to normal levels by the restoration of BCR/ABL expression. Generally speaking, miR320a acts as a novel tumor suppressor gene in CML and miR-320a can decrease migratory, invasive, proliferative and apoptotic behaviors, as well as CML EMT, by attenuating the expression of BCR/ABL oncogene.
MiR-320a inhibits K562 migration, invasion, proliferation and induces apoptosis by BCR/ ABL.
To examine the functional significance of miR-320a overexpression in K562, we infected the CML cell line K562 with LV-hsa-miR-320a. Compared with the expression of cont-miR, miR-320a was significantly overexpressed in the K562 after infection with LV-hsa-miR-320a ( Fig. 2A) . We also found that, comparing with cont-miR, the expression of BCR/ABL was significantly downregulated in the K562 cell lines after infection with LV-hsa-miR-320a (Fig. 2B ). The cells with forced expression of miR-320a exhibited significantly decreased proliferation compared with the cells with forced expression of cont-miR (Fig. 2C) . The miR-320a-infected cells also exhibited reduced colony formation ability: the number of foci in the miR-320a-expressing cells was decreased compared with the cont-miR-infected cells (Fig. 2D) . miR-320a could regulate the expression of BCR/ABL by directly inhibiting BCR/ABL transcript or other indirect circuits, so we next ascertained whether the reduction of BCR/ABL expression could explain the inhibition of CML cell migration, invasion and proliferation observed after the forced expression of miR-320a. We therefore forced the expression of miR-320a in K562 cells together with a construct containing the BCR/ABL coding sequence but lacking the 3′ UTR of the BCR/ABL mRNA. As a result, this construct yielded a BCR/ABL mRNA that was resistant to miR-320a. We found that CML cell migration, invasion, proliferation and apoptosis were restored in the K562 cell line with forced miR-320a expression and BCR/ABL restoration ( Fig. 2E-G) . Those results show that miR-320a inhibits CML cell migration, invasion and proliferation and promotes apoptosis by targeting its BCR/ABL oncogene.
Overexpression of miR-320a prohibits tumorigenesis and promotes apoptosis in vivo.
We next examined whether overexpression of miR-320a could suppress tumor growth and induce apoptosis in vivo. Retrovirus-mediated K562/miR-320a and K562/miR-control stable cell lines were obtained as described in the retroviral transfection for stable cell lines section. RV-miR-320a, RV-miR-control or K562 cells were injected subcutaneously into nude mice, and tumor formation was monitored. After 35 days, the mice were euthanized and tumor weights were measured. Tumors grew faster in RV-miR-control and parental cell K562 group than that in the group of RV-miR-320a (Fig. 3A-D) . The average weight of tumors resulting from RV-miR-320a was significantly less than tumors derived from RV-miR-control or K562 cells (670 ± 130 mg vs. 1810 ± 420 mg, 1980 ± 220 mg; p < 0.01). There was no significant difference in the tumor volume or in the weight between RV-miR-control or K562 cells.
In addition, the number of Ki-67-antigen-positive cells was lower in the tumor derived from RV-miR320a cells than that in RV-miR-control or K562 cells (p < 0.01, Fig. 3E ). The results revealed that the decreased tumor growth in mice was, in part, due to lower proliferation caused by the overexpression of miR-320a. Thus, tumorigenicity was significantly reduced in RV-miR-320a cells in vivo. To assess whether tumor growth inhibition in RV-miR-320a was due partly to the induction of apoptosis partly, TUNEL assays of tumor tissues were performed. As shown in Fig. 3E , the RVmiR-320a cells showed a more tumor cell positive staining and a significantly higher apoptotic index than the K562/vector or K562 cells (P < 0.01). These results suggested that miR-320a inhibition of tumorigenicity was attributed to decreased proliferation and increased apoptosis in vivo.
Scientific RepoRts | 5:12460 | DOi: 10.1038/srep12460 miR-320a directly targets and inhibits BCR/ABL. To understand how miR-320a suppress CML growth and metastasis, we used three algorithms (Targetscan, Pictar and Miranda) to help identify miR320a targets in human CML. Of these target genes that were predicted by all three algorithms, BCR/ABL attracted our attention immediately as it has been implicated in tumorigenesis or metastasis and proved to be the oncogene previously.
We cloned the full-length BCR/ABL 3′ -UTR into a luciferase reporter vector. Luciferase assay revealed that miR-320a directly bound to BCR/ABL 3′ -UTR, and by which it remarkably reduced luciferase activities (Fig. 4A) . However, mutation of the putative miR-320a sites in the 3′ -UTR of BCR/ABL abrogated luciferase responsiveness to miR-320a (Fig. 4A ). To directly assess the effect of miR-320a on BCR/ABL expression, we performed western blot analysis. As seen in Fig. 4B , lentiviral induced ectopic miR-320a dramatically suppressed the BCR/ABL protein levels in K562 cells. Furthermore, knockdown of miR320a, through transfection of anti-miR-320a, in A562 cells increased BCR/ABL protein levels (Fig. 4B) . Taken together, these results indicate that BCR/ABL is a direct downstream target for miR-320a in CML cells. To further elucidate the relationship between miR-320a and BCR/ABL expression in primary samples, we did the scatter plot and the Pearson correlation analysis, the results indicated that miR-320a expression was negatively correlated with the target protein levels in the CML samples (Fig. 4C) . −△Ct values (**P < 0.01). (D). Survival analysis of CML. OS and RFS curves for 90 CML patients with high or low miR-320a expression were constructed using the Kaplan-Meier method and evaluated using the log-rank test.
The above results prompted us to examine whether miR-320a suppresses CML growth and metastasis through repressing BCR/ABL expression. For this purpose, BCR/ABL was re-expressed in miR-320a transfected K562 cells. In miR-320a-expressing cells, re-expression of BCR/ABL rescued the invasion and growth defects of miR-320a (Fig. 4D-F ). Finally, we tested if miR-320a expression correlated with BCR/ABL protein levels in CML. There was an inverse correlation between the BCR/ABL protein levels, indicated by immunohistochemistry staining, and miR-320a expression assessed by in situ hybridization in 90 CML cancer stem cells on TMAs as used above (Fig. 4G ).
MiR-320a regulates CML pathogenesis by targeting BCR/ABL induced PI3K/AKT/ NF-κB signaling pathways. CML is a clonal hematopoietic stem cell disorder characterized by the t (9;22) chromosome translocation and resultant production of the constitutively activated BCR/ABL tyrosine kinase and it has been proved to be the tumor oncogene. PI3K signaling pathway was indicated to be induced by BCR/ABL by our past study. Because BCR/ABL is a downstream target of miR-320a, we assumed that miR-320a could decrease the expression of the phosphorylation of PI3K, AKT, and NF-κ B. We found that the forced expression of miR-320a inhibited the phosphorylation of PI3K, but the relative expression (D) miR-320a overexpression significantly inhibited the colony-forming ability of K562. (E-G) K562 cell migration, invasion, proliferation and apoptosis were restored after BCR/ABL restoration. The data represent the means ± s.d.; *p < 0.001, **p < 0.05, ***p < 0.01. level of total PI3K was not significantly altered. miR-320a could also decrease the phosphorylation of AKT and NF-κ B (Fig. 5A ). miR-320a could bind the 3′ UTR of the BCR/ABL mRNA to regulate the phosphorylation of PI3K, AKT and NF-κ B; however, we did not know whether miR-320a could bind the 3′ UTRs of other genes to achieve an equal effect. So rescue experiment was performed, and the restoration of BCR/ABL expression was confirmed through an immunoblot analysis (Fig. 5B) . We found that the phosphorylation levels of PI3K, AKT and NF-κ B were not significantly altered in the K562 cells with forced miR-320a expression and BCR/ABL restoration (Fig. 5C ). Therefore, we conclude that miR320a regulates the phosphorylation of PI3K, AKT and NF-κ B via BCR/ABL.
MiR-320a controls the epithelial phenotype of CML.
EMT is an important mechanism associated with cancer invasiveness and metastasis. The phenomenon of EMT is defined as the transition of epithelial cells to fibroblastoid-or mesenchymal-like cells. EMT is characterized by the loss of epithelial markers and the acquisition of mesenchymal components. Ecadherin, occludin and cytokeratin are downregulated during EMT, whereas N-cadherin, vimentin and fibronectin are upregulated. To find the role of BCR/ABL in sustaining the mesenchymal phenotype of CML cells, we knocked down the expression of BCR/ABL by RNA interference (RNAi) (Fig. 6A ) and examined the expression of mesenchymal markers such as fibronectin, N-cadherin E-cadherin and vimentin in K562 cells. We found that the expression levels of fibronectin, vimentin and N-cadherin were decreased but the expression of E-cadherin was increased in the BCR/ABL-depleted tumor stem cells (Fig. 6B) . The result shows that BCR/ABL can drive EMT process in CML. Because BCR/ABL is a downstream target of miR-320a, we assumed that miR-320a could determine the epithelial phenotype of CML. To determine whether the molecular changes typical of a reduced EMT occurred in miR-320a-expressing cells, we examined the expression of mesenchymal and epithelial markers in K562. The immunoblot analysis showed that the expression levels of fibronectin, vimentin and N-cadherin were decreased in the K562 with the forced expression of miR-320a. Furthermore, the forced expression of miR-320a increased the expression of E-cadherin in the K562 cell line, whereas the control-infected cells remained E-cadherin negative. We found that miR-320a regulated the phosphorylation of PI3K, AKT and NF-κ B via BCR/ABL; therefore, we detected whether miR-320a could regulate EMT via BCR/ABL. The immunoblot analysis showed that the expression of the above mesenchymal markers in the miR-320a-expressing cells was restored to the normal level by the restoration of BCR/ABL expression (Fig. 6C) . Altogether, these results demonstrated that miR-320a could inhibit EMT via BCR/ABL in CML.
Discussion
Expression of the Philadelphia chromosome (Ph), the t (9;22) chromosomal translocation and the formation of the BCR/ABL fusion protein, is the hallmark of chronic myeloid leukemia (CML) 14, 15 . The BCR/ABL1 oncogene contributes to the development of CML clones 16 . Although Interferon-α , Imatinib (a BCR/ABL tyrosine kinase inhibitor) and stem cell transplantations are the standard therapeutic options, transplant-related morbidity from graft-versus-host disease and mortality rates of 10% to 20% have greatly reduced the allogeneic hematopoietic cell transplantation in clinics, while interferon-α is only effective in some patients to some degree and chemotherapeutic intervention does not result in prolonged overall survival and the reason is possibly due to some unknown biology of the CML cancer stem cells especially the regulating molecule mechanisms [17] [18] [19] . Our laboratory have identified the Flk-1 + CD34-CD31-hemangioblasts as the CML initiating cells and proved the rearrangement of the BCR/ABL gene might happen at the level of this hemangioblastic progenitor cells instead of HSCs 20 . Based on this concept, we first used qRT-PCR and ISH to show that miR-320a levels in CML cancer stem cells were significantly lower than the normal MSCs in healthy donors. Moreover, the miR-320a levels were associated with the clinical stage and presence of lymph node metastases. Kaplan-Meier survival analysis revealed that patients whose MSCs displayed low expression of miR-320a had a shorter OS and RFS in CML. In addition, Cox proportional hazards regression analysis showed that reduced miR-320a in CML was a strong and independent predictor of shorter OS and RFS. Moreover, the overexpressed miR-320a could inhibit K562 cell migration, invasion and proliferation, and promote apoptosis. Meanwhile, those tumourigenic qualities can be completely restored by BCR/ABL overexpression. In addition, the luciferase reporter assays suggested that miR-320a targets BCR/ABL oncogene directly. Thus, we conclude that miR-320a acts as a potential tumor suppressor in CML, a function that is accomplished by curbing the expression of BCR/ABL. As an oncogene, BCR/ABL played important roles in the pathogenesis in CML [21] [22] [23] [24] . More and more signaling pathways were proved to be involved in the regulation of BCR/ABL on CML [25] [26] [27] . In this study, we found that overexpressed miR-320a could decrease the expression of the phosphorylation of PI3K, AKT and NF-κ B, an effect that was reversed upon BCR/ABL restoration. The activation of PI3K, AKT and NF-κ B in association with apoptosis resistance/cell survival has been well documented in a variety of model systems [28] [29] [30] . Thus, we conclude that miR-320a inhibits CML cell migration, invasion and proliferation, as well as promoting apoptosis, by decreasing the expression of BCR/ABL, which increases PI3K, AKT and NF-κ B signaling.
The phenotypic transition from an epithelial to a mesenchymal like cell state represents an important mechanism of epithelial plasticity and cancer metastasis [31] [32] [33] . MicroRNAs have recently emerged as potent regulators of EMT due to their ability to target multiple components involved in epithelial integrity or mesenchymal traits. The miR-200 family has been shown to directly target EMT transcription factor families 34 . In human mammary epithelial cells, miR-9 directly targets E-cadherin, thus promoting the mesenchymal phenotype, including increased cell migration and invasion 35 . MiR-27 promotes human gastric cancer cell metastasis by inducing the epithelial-to-mesenchymal transition 36 . We thereby performed the assay that tested the relationships between miR-320a and EMT, and our in vitro experiments strongly demonstrated that miR-320a promote EMT of CML. Furthermore, we found higher phosphorylation of PI3K, AKT and NF-κ B when we test the EMT hallmark N-cadherin, vimentin, fibronectin and E-cadherin of K562 transfected with miR-320a. Interestingly, blocking the PI3K/AKT/NF-κ B pathway cancelled the effect of miR-320a, which might provide a more comprehensive picture of the molecular network that miR-320a promoted EMT through activating PI3K/AKT/NF-κ B pathway in metastasis of CML.
Material and Methods
Patient samples. 90 patients with newly diagnosed CML (49 male and 41 female, aged 17-71 years)
were recruited in this study. All were Ph + patients with CML in chronic phase as revealed by bone marrow histology and cytogenetic analysis and the immunophenotypes of thawed cells were quite variable. None was treated with hydroxyurea or interferon before. The control samples were from 90 healthy donors (48 male and 42 female, aged 19-68 years). They were all Ph + negative at donation. Bone marrow samples were collected after obtaining informed consent according to procedures approved by the Ethics Committee at the Institute of the 309 th hospital of People's Liberation Army.
Cell preparations and culture conditions. Isolation and culture of bone marrow-derived BCR/ABL + MSCs from CML patients were performed as described previously with some modifications [19] [20] [21] . Briefly, mononuclear cells were separated by a Ficoll-Paque gradient centrifugation (specific gravity 1.077 g/mL; Nycomed Pharma AS, Oslo, Norway) and the sorted cells were plated at concentration of 1 cell/well by limiting dilution in a total of 96 × 10 wells coated with fibronectin (Sigma, St Louis, MO) and collagen (Sigma) for each patient. Culture medium was Dulbecco modified Eagle medium and Ham F12 medium (DF12) containing 40% MCDB-201 medium complete with trace elements (MCDB) (Sigma), 2% fetal calf serum (FCS; Gibco Life Technologies, Paisley, United Kingdom), 1 × insulin transferrin selenium (Gibco Life Technologies), 10 −9 M dexamethasone (Sigma), 10 −4 M ascorbic acid 2-phosphate (Sigma), 20 ng/mL interleukin-6 (Sigma), 10 ng/mL epidermal growth factor (Sigma), 10 ng/mL platelet-derived growth factor BB (Sigma), 50 ng/mL fetal liver tyrosine kinase 3 (Flt-3) ligand (Sigma), 30 ng/mL bone morphogenetic protein-4 (Sigma), 100 U/mL penicillin and 100 ug/mL streptomycin (Gibco Life Technologies) at 37 °C and a 5% CO 2 humidified atmosphere. Culture media were changed every 4 to 6 days.
RT-PCR.
RNA isolation and reverse transcription were performed as previously described 32 . Oligonu cleotide primer sequences were as follows: β -actin (264 bp), forward: 5′ -GAG ACC TTC AAC ACC CCA GCC-3′ ; reverse:5′ -AAT GTC ACG CAC GAT TTC CC-3′ ; BCR/ABL (271 bp), forward: 5′ -AGA GGT CTC AGA AGG GAC CG-3′ , reverse: 5′ -GGG CCA TAC AGG ACA CGA AG-3′ ; PI3K (174 bp), forward: 5′ -TGC TTT TTC CAG GGG TGT GTT-3′ , reverse: 5′ -TAC TTC CTG CAC TAA TTT GGC A-3′ ; AKT (201 bp), forward: 5′ -GGA AAC CCA CAA CGA AAT CTA TGA C-3′ , reverse: 5′ -TTG CTG AGG TAT CGC CAG GAA T-3′ ; NF-κ B (225 bp), forward: 5′ -CGC CAA GGA GGT TTA CAA AAT AGA C-3′ , reverse: 5′ -TCA ATC CGT TGT TCA GGC ACT CT-3′ . For all the above genes, amplification was performed under the same cycling conditions (1 minute at 94 °C, 50 seconds at 57 °C, 1 minute at 72 °C), except the number of cycles that were specified for each gene (31 for BCR/ABL ` PI3K and AKT, 32 for NF-κ B).
Western blot and Immunopreciptation. MSCs were harvested at specific times after treatment with reagents as indicated in each experiment. Cells were mixed with loading buffer and subjected to electrophoresis. After electrophoresis proteins were transferred to polyvinyl difluoride membranes (Pall Filtron) using a semidry blotting apparatus (Pharmacia) and probed with mouse monoclonal antibodies, followed by incubation with peroxidase-labeled secondary antibodies. Detection was performed by the use of a chemiluminescence system (Amersham) according to the manufacturer's instructions. Then membrane was striped with elution buffer and reprobed with antibodies against the nonphosphorylated protein as a measure of equal loading. Controls for the immunoprecipitation used the same procedure, except agarose beads contained only mouse IgG.
RNA-i experiments.
The si-RNA sequence targeting human BCR/ABL (from mRNA sequence; Invitrogen online) corresponds to the coding region 286-314 relative to the first nucleotide of the start codon (target = 5′ -ATC TTC ACT CAA TAG GTA CGA ACG GC-3′ ). Computer analysis using the software developed by Ambion Inc. confirmed this sequence to be a good target. si-RNAs were 21 nucleotides long with symmetric 2-nucleotide 3′ overhangs composed of 2′ -deoxythymidine to enhance nuclease resistance. The si-RNAs were synthesized chemically and high pressure liquid chromatography purified (Genset, Paris, France). Sense si-RNA sequence was 5′ -UAC TAC CAA AUG UAT CCT AdTdT-3′ . Antisense si-RNA was 5′ -AUG AAT CTA AUC GTU GAA GdTdA-3′ . For annealing of si-RNAs, mixture of complementary single stranded RNAs (at equimolar concentration) was incubated in annealing buffer (20 mM Tris-HCl pH 7.5, 50 mM NaCl, and 10 mM MgCl 2 ) for 2 minutes at 95 °C followed by a slow cooling to room temperature (at least 25 °C) and then proceeded to storage temperature of 4 °C. Before transfection, cells cultured at 50% confluence in 6-well plates (10 cm 2 ) were washed two times with OPTIMEM 1 (Invitrogen) without FCS and incubated in 1.5 ml of this medium without FCS for 1 hour. Then, cells were transfected with BCR/ABL-RNA duplex formulated into Mirus TransIT-TKO transfection reagent (Mirus Corp, Interchim, France) according to the manufacturer's instructions. Unless otherwise described, transfection used 20 nM RNA duplex in 0.5 ml of transfection medium OPTIMEM 1 without FCS per 5 × 10 5 cells for 6 hours and then the medium volume was adjusted to 1.5 ml per well with RPMI 2% FCS. SilencerTM negative control 1 si-RNA (Ambion Inc.) was used as negative control under similar conditions (20 nM). The efficiency of silencing is 80% in our assay.
Migration and invasion assays. We used a Transwell insert (24-well insert, pore size 8 lm; Corning, Inc., Corning, NY) to determine the effect of miR-320a on K562 migration and invasion in vitro. Briefly, the transfected cells were first starved in serum-free medium overnight, and 3 × 10 4 cells were re-suspended in serum-free medium and placed in the top chambers in triplicate. The lower chamber was filled with 10% FBS as the chemo-attractant and incubated for 48 h for the migration assay and 72 h for the invasion assay. For the invasion assay, the inserts were previously coated with extracellular matrix gel (BD Biosciences, Bedford, MA). At the end of the experiments, the cells on the upper surface of the membrane were removed, and the cells on the lower surface were fixed and stained with 0.1% crystal violet. Five visual fields of each insert were randomly chosen and counted under a light microscope.
Colony formation assay. Six-well plates were covered with a layer of 0.6% agar in medium supplemented with 20% fetal bovine serum. Cells were prepared in 0.3% agar and seeded in triplicate. After the plates were incubated at 37☐ for two weeks, the colonies were counted.
Apoptosis analysis. The apoptotic cells were evaluated by Annexin V-FITC and propidium iodine staining (BD, USA) and analyzed with a FACS Calibur instrument (BD, USA). The collected data were analyzed using flow soft ware.
Tumor-bearing (Xenografts) study. As reported recently 7 , 1.5 × 10 5 K562 cells re-suspended in 150 ul PBS were injected subcutaneously into the flank of the normal C57B/l6 mice at age about 8 weeks (5 mice per group). Both K562 and the mice were in C57BL/6 background and no rejection occurred. The animals were maintained in a pathogen-free barrier facility and closely monitored by animal facility staff. The grown tumors (xenografts) were measured every 3 day starting 23 days post inoculation of cells using caliper as length × width × width/2 (mm 3 ). 6.3 ug of miR-320a precursor or negative miRNA (GenePharma, Shanghai, China) mixed with 1.6 ul transfection reagent Lipofectamine 2000 (Invitrogen) in 50 ul PBS were injected into the tumors every 3 days, for total of 3 times. 32 days after inoculation, the animals were sacrificed and the xenografts were isolated, the weight (gram) and volume (mm 3 ) of the xenografts were determined. All procedures were conducted according to the Animal Care and Use guideline approved by Xinxiang Medical University Animal Care Committee.
Statistical Analysis. Student's t-test (two-tailed), One-way ANOVA and Mann-Whitney test were employed to analyze the in vitro and in vivo data using SPSS 12.0 software (Chicago, IL, USA). P value < 0.05 was defined as statistically significant.
